These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3093918)

  • 1. Transfer factor therapy in multiple sclerosis: a three-year prospective double-blind clinical trial.
    Van Haver H; Lissoir F; Droissart C; Ketelaer P; Van Hees J; Theys P; Vervliet G; Claeys H; Gautama K; Vermylen C
    Neurology; 1986 Oct; 36(10):1399-402. PubMed ID: 3093918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer factor as a therapy for multiple sclerosis: a follow-up study.
    Frith JA; McLeod JG; Basten A; Pollard JD; Hammond SR; Williams DB; Crossie PA
    Clin Exp Neurol; 1986; 22():149-54. PubMed ID: 3555898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer factor in treatment of multiple sclerosis.
    Basten A; McLeod JG; Pollard JD; Walsh JC; Stewart GJ; Garrick R; Frith JA; Van Der Brink CM
    Lancet; 1980 Nov; 2(8201):931-4. PubMed ID: 6107585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.
    Collins RC; Espinoza LR; Plank CR; Ebers GC; Rosenberg RA; Zabriskie JB
    Clin Exp Immunol; 1978 Jul; 33(1):1-11. PubMed ID: 361313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term transfer-factor treatment for multiple sclerosis.
    Fog T; Pedersen L; Raun NE; Kam-Hansen S; Mellerup E; Platz P; Ryder LP; Jakobsen BK; Grob P
    Lancet; 1978 Apr; 1(8069):851-3. PubMed ID: 76798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma.
    Miller LL; Spitler LE; Allen RE; Minor DR
    Cancer; 1988 Apr; 61(8):1543-9. PubMed ID: 3280114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients.
    Lamoureux G; Cosgrove J; Duquette P; Lapierre Y; Jolicoeur R; Vanderland F
    Clin Exp Immunol; 1981 Mar; 43(3):557-64. PubMed ID: 7026094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfer factor for adjuvant immunotherapy in cervical cancer.
    Wagner G; Knapp W; Gitsch E; Selander S
    Cancer Detect Prev Suppl; 1987; 1():373-6. PubMed ID: 3319147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfer-factor therapy in multiple sclerosis.
    Behan PO; Durward WF; Melville ID; McGeorge AP; Behan WM
    Lancet; 1976 May; 1(7967):988-90. PubMed ID: 57441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transfer factors in medical therapy].
    Sánchez-González DJ; Sosa-Luna CA; Vásquez-Moctezuma I
    Med Clin (Barc); 2011 Sep; 137(6):273-7. PubMed ID: 20561650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.
    Brochet B; Guinot P; Orgogozo JM; Confavreux C; Rumbach L; Lavergne V
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):360-2. PubMed ID: 7897422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transfer factor as adjuvant immunotherapy in invasive cervix cancer. Report of a double-blind study].
    Wagner G; Gitsch E; Havelec L; Knapp W; Rainer H; Selander S
    Wien Klin Wochenschr; 1983 Oct; 95(20):738-42. PubMed ID: 6362210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfer factor and hepatitis B: a double blind study.
    Ellis-Pegler R; Sutherland DC; Douglas R; Woodfield DG; Wilson JD
    Clin Exp Immunol; 1979 May; 36(2):221-6. PubMed ID: 477025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.
    Ann Neurol; 1990 Jun; 27(6):591-605. PubMed ID: 2193613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of clinico-immunological testing of myelopid in chronic forms of multiple sclerosis].
    Gusev EI; Demina TL; Boĭko AN; Popova NF; Stepanenko RN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):18-25. PubMed ID: 1326165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.